Navigation Links
Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions

COLUMBIA, Md., Aug. 20 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that it has entered into a multi-year, sole-source supply agreement with Milk Powder Solutions, based in Australia. Under the terms of the agreement, Martek will serve as Milk Powder Solutions' exclusive supplier for all of its ARA needs for infant formula products in China and Vietnam under the Gold Cow brand name.

"This new agreement with Milk Powder Solutions is another important step in Martek's effort to expand its international presence in the infant formula market," said Ethan Leonard, vice president of pediatric nutrition for Martek. "We believe this agreement again demonstrates that companies around the world continue to recognize the importance of adding Martek's trusted source of ARA to products for infants and children."

Naturally present in human breast milk, ARA (arachidonic acid) is a fatty acid important to infant development and growth. Clinical studies have demonstrated numerous benefits, including improved mental and visual development, for infants receiving infant formula supplemented with ARA and DHA (docosahexaenoic acid), another fatty acid important to infant development. Martek's blend of DHA and ARA, life'sDHA & life'sARA(TM), is the only source of these nutrients currently used in U.S. infant formula, and is present in more than 95 percent of infant formula sold in the U.S. Additionally, Martek is a leading global supplier of DHA and ARA and infant formulas containing Martek's nutritional oils are available in more than 75 countries worldwide.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA, a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit

The Milk Powder Solutions Company is a specialized dairy ingredient supplier. They have developed a range of unique dairy products for industrial and domestic use. Milk Powder Solutions' objective is to utilize Australian and selected international regions that can offer superior clean dairy products competitively priced in very large volumes. For more information please visit

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.


    Cassie France-Kelly
    Public Relations
    (443) 542-2116

    Kyle Stults
    Investor Relations
    (410) 740-0081

SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Martek to Announce Third Quarter 2009 Results
2. Martek Signs Sole-Source ARA Supply Agreement with Puleva Food S.L.
3. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
4. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
5. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
6. EU Committee Approves New Food Applications for Martek's life'sDHA™
7. Martek to Host Investor Conference Call to Discuss Research Presented at the International Conference on Alzheimers Disease in Vienna, Austria
8. Martek to Present at Upcoming Needham Conference
9. Martek to Announce Second Quarter 2009 Results
10. Martek Announces First Quarter 2009 Financial Results
11. Martek, General Mills Collaborate on Microencapsulation Technology for Food Applications
Post Your Comments:
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):